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The image shows the 4 stable subtypes of triple-negative breast cancer defined by gene signature.
These subtypes (luminal androgen receptor, mesenchymal, basal-like immunosuppressed, and
basal-like immune-activated) are characterized by the expression of distinct molecular profiles
that have disparate prognoses. For details, see the article by Burstein and colleagues on page 1688 of
this issue.
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